Sorafenib is a Medicine belongs to Antineoplastic group whose information about Brand can be referenced from   Book : Martindale    Page : 850   Edition : 37  

  ►   Brandname : Nexavar
  ►  Strength : Tablet with 200 Mg. 

Reference of this Medicine for its Strength can be taken from   Book : Martindale    Page : 850   Edition : 37  
A Route of administration in pharmacology and toxicology is the path by which a drug, fluid, poison, or other substance is taken into the body. Routes of administration are generally classified by the location at which the substance is applied. Common examples include oral and intravenous administration.

  ►  Route of administration : Oral
Reference :-   Book : Martindale    Page : 850   Edition : 37  

Dosing of Medicine differ in Adult & Pediatrics ↓

Adult Dose

S.No Ailment   Route   Dose Min   Dose Max   Unit   Dosage Form   Frequency   Additional Info
1 Advanced renal cell carcinoma and hepatocellular carcinoma Oral 400 mg Tablet b.d. Dose: Given at least 1 hour before or 2 hours after food. Treatment is continued until no clinical benefit is seen or until unacceptable toxicity occurs. Doses are reduced to 400 mg once daily if toxicity occurs; further reduction to a single dose of 400 mg every other day may be necessary.

Ref :-  Book : Martindale    Page : 850   Edition : 37  



Pediatric Dose

S.No Ailment   Age Min   Age Max   Weight ( Kg ) Route   Dose Min   Dose Max   Unit   Dosage Form   Frequency  Additional Info  
1

Ref :- Book :    Page :    Edition :   
►  Side Effect : Diarrhoea, Palmar-plantar syndrome, Rashes, Congestive heart failure, Cardiac failure, Myocardial infraction, Mild to moderate hypertension, Cardiac ischemia, Leukopenia, Lymphopenia, Anaemia, Neutropenia, Thrombocytopenia, Hypophosphataemia, Transient disturbances in liver function tests, Elevations in lipase and amylase concentrations, Pancreatitis, Alopecia, pruritus, Dry skin, Erythema, Acne, Flushing, Exfoliative dermatitis, Hoarseness, Gastrointestinal disturbances, Arthralgia, Myalgia, Asthenia, Pain, Peripheral neuropathies, Tinnitus, Depression, Erectile dysfunction, Pyrexia, Flu-like illness, Weight decrease, Hypersensitivity reactions, Changes in thyroid function, Hyponatraemia, Gynaecomastia, Stevens-Johnson syndrome
Ref :-   Book : Martindale    Page : 850   Edition : 37.  

►  Drug Interaction : Drug interaction of Sorafenib is with Carbamazapine , Dexamethasone , Phenobarbital , Phenytoin , Ketoconazole , Midazolam , Omeprazole , Dextromethorphan , Warfarin , Docetaxel, Doxorubicin, Irinotecan
Ref :-   Book : Martindale    Page : 850, 1568   Edition : 37.  


  ►    Mechanism of Drug Drug Interaction :  Sorafenib is metabolised by the cytochrome P450 isoenzyme CYP3A4. Rifampicin can reduce exposure to sorafenib. Other inducers of this enzyme (such as carbamazepine, dexamethasone, St John’s wort, phenobarbital, and phenytoin) may also reduce blood concentrations of sorafenib. However, ketoconazole did not alter exposure to sorafenib and other drugs that inhibit CYP3A4 are considered unlikely to alter the metabolism of sorafenib. In vitro studies have indicated that sorafenib itself inhibits the cytochrome P450 isoenzymes CYP3A4, CYP2C19, and CYP2D6, but use of sorafenib with midazolam, or omeprazole, or dextromethorphan did not alter the exposure to any of these drugs; interactions with drugs that are substrates of these enzymes are considered unlikely. Sorafenib inhibits the cytochrome P450 isoenzyme CYP2C9 in vitro, and may increase concentrations of its substrates. Elevated INR and bleeding events have been reported with the use of sorafenib and warfarin. Sorafenib also inhibits the isoenzymes CYP2B6 and CYP2C8 in vitro, and drug interactions with substrates of these may occur. Sorafenib may increase exposure to docetaxel, doxorubicin, and irinotecan; variable effects on fluorouracil have been reported. .
Ref :-   Book : Martindale    Page : 850, 1568   Edition : 37.  


►  Contraindication : Pregnancy, Breast feeding, Great caution is needed when the marrow is already depressed from radiotherapy or therapy with other antineoplastics, and modification of dosage regimens may be required
Ref :-   Book : Martindale    Page : 697, 850   Edition : 37.  
  ►  Mechanism of Action :   Sorafenib is an inhibitor of multiple intracellular and cell surface kinases thought to be involved in angiogenesis.
Ref :-   Book : Martindale    Page : 850   Edition : 37.  

Pathway of DIETARY Product


​   ► Act.Comp / Nutrient / Food / Herb as follows :- NA


DIETARY Substance Interactions


​   ► This Medicine interact with :- NA



ContraIndication DIETARY Substance


​   ► This Medicine contraindicate with :- NA

►   Route of Elimination :   Renal, Faecal
Ref :-   Book : Martindale    Page : 850   Edition : 37.  

►    Plasma Half-life :   Min value :-   25 hours,    Max value :-   48 hours.  
Ref :-   Book : Martindale    Page : 850   Edition : 37.  

►    Peak Plasma Concentration :   Min value :-   3 hours,    Max value :-   NA
Ref :-   Book : Martindale    Page : 850   Edition : 37.